

Publications in peer-reviewed indexed journals

1. Roberto G, Paoletti O, **Ferraro S**, Hyeraci G, Franchini M, Gini R, Focosi D, Tuccori M. Cases of acquired hemophilia A following COVID-19 vaccines: cogent safety signal or possible reporting/detection bias? Preliminary evidence from Tuscany, Italy. *Pharmacoepidemiol Drug Saf.* 2023. Doi: 10.1002/pds.5615
2. Convertino I, **Ferraro S**, Cappell E, Valdiserra G, Bonaso M, Tuccori M. Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence. *Expert Opin Drug Discov.* 2023 Mar;18(3):231-245. 10.1080/17460441.2023.2170348
3. Tuccori M, Convertino I, **Ferraro S**, Cappello E, Valdiserra G, De Luca G, Franchini M, Focosi D. Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall. *Drug Discov* 2022 Jun;17(6):531-546. doi: 10.1080/17460441.2022.2058486.
4. Cucchiara F, **Ferraro S***, Luci G, Bocci G. Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data. *Pharmacol Res.* 2021 Nov 14;175:105976. doi: 10.1016/j.phrs.2021.105976. [***co-first author**]
5. Convertino I, Giometto S, Gini R., Cazzato M., Fornili M., Valdiserra G., Cappello E., **Ferraro S.**, Bartolini C., Paoletti O., Tillati S., Baglietto L., Turchetti G., Trieste L., Lorenzoni V., Blandizzi C., Mosca M., Tuccori M., Lucenteforte E. Trajectories of adherence to biologic disease-modifying anti-rheumatic drugs in tuscan administrative databases: The pathfinder study. doi: (2021) *Journal of Clinical Medicine*, 10 (24) doi: 10.3390/jcm10245743
6. Convertino I, Cazzato M, Giometto S, Gini R, Valdiserra G, Cappello E, **Ferraro S**, Tillati S, Bartolini C, Paoletti O, Lorenzoni V, Trieste L, Filippi M, Turchetti G, Cristofano M, Blandizzi C, Mosca M, Lucenteforte E, Tuccori M. Validation of algorithms for selecting rheumatoid arthritis patients in the Tuscan healthcare administrative databases. *Sci Rep.* 2021 Oct 13;11(1):20314. doi: 10.1038/s41598-021-98321-0.
7. Convertino I, Lucenteforte E, Gini R, Lorenzoni V, Cazzato M, Turchetti G, Trieste L, **Ferraro S**, Leonardi L, Roberto G, Luciano N, Blandizzi C, Mosca M, Tuccori M. Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons. *Clin Exp Rheumatol.* Jul-Aug 2021;39(4):753-762. Doi: 10.55563/clinexprheumatol/pa6lap.
8. Tuccori M, Convertino I, **Ferraro S**, Valdiserra G, Cappello E, Fini E, Focosi D. An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future. *Expert Opin Drug Discov.* 2021 Dec;16(12):1403-1414. doi: 10.1080/17460441.2021.1960819.
9. **Ferraro S**, Tuccori M, Convertino I, Valdiserra G, Cappello E, Maggi F, Blandizzi C, Focosi D. Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs. *Br J Clin Pharmacol.* 2021;87(5):2186-2188. doi:10.1111/bcp.14634
10. Tuccori M, **Ferraro S**, Convertino I, Cappello E, Valdiserra G, Blandizzi C, Maggi F, Focosi D. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. *MAbs.* 2020;12(1):1854149. doi:10.1080/19420862.2020.1854149
11. Pagani S, Lombardi N, Crescioli G, Vighi G V, Spada G, Romoli I, Andreetta P, Capuano A, Marrazzo E, Marra A, Leoni O, Vannacci A, Venegoni M, Vighi GD, Bettoni D, Blandizzi C, Bonaiuti R, Borsi V, Cecchi E, Convertino I, Del Lungo M, Di Mauro C, Farina G, **Ferraro S**, Fucile A, Galfrascoli E, Geninatti E, Giovannetti L, Leonardi L, Liccardo R, Monina G, Mugelli A, Pagani S, Parrilli M, Rafaniello C, Rossi F, Rostan S, Ruocco M, Sironi M, Sportiello L, Tuccori M, MEREAFaPS Study group. Analysis of fatal adverse drug events recorded in several Italian emergency departments (the MEREAFaPS study). *Intern Emerg Med.* Published online 2021. doi:10.1007/s11739-020-02521-x
12. Lombardi N, Bettioli A, Crescioli G, Ravaldi C, Bonaiuti R, Venegoni M, Vighi GD, Mugelli A, Mannaioni G, Vannacci A, Aiezza ML, Bettoni D, Blandizzi C, Borsi V, Capuano A, Cecchi E, Convertino I, Lungo MD, Mauro CD, Farina G, **Ferraro S**, Fucile A, Galfrascoli E, Geninatti E, Giovannetti L, Leonardi L, Liccardo R, Marra A, Marrazzo E, Monina G, Pagani S, Parrilli M, Rafaniello C, Rossi F, Rossi M, Rostan S, Ruocco M, Sironi M, Spada G, Sportiello L, Tuccori M, Vighi G V, the MEREAFaPS Study group. Risk of hospitalisation associated with benzodiazepines

- and z-drugs in Italy: a nationwide multicentre study in emergency departments. *Intern Emerg Med*. 2020;15(7):1291-1302. doi:10.1007/s11739-020-02339-7
13. Tuccori M, Convertino I, **Ferraro S**, Cappello E, Valdiserra G, Focosi D, Blandizzi C. The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance. *Drug Saf*. 2020;43(8):699-709. doi:10.1007/s40264-020-00965-w
 14. Lombardi N, Crescioli G, Bettiol A, Tuccori M, Capuano A, Bonaiuti R, Mugelli A, Venegoni M, Vighi GD, Vannacci A, Aiezza ML, Bettoni D, Blandizzi C, Borsi V, Cecchi E, Convertino I, Del Lungo M, Di Mauro C, Farina G, **Ferraro S**, Fucile A, Galfrascoli E, Geninatti E, Giovannetti L, Leonardi L, Liccardo R, Marra A, Marrasso E, Monina G, Pagani S, Parrilli M, Rafaniello C, Rossi F, Rossi M, Rostan S, Ruocco M, Sironi M, Spada G, Sportiello L, Vighi GD, the MEREAFaPS Study group. Italian Emergency Department Visits and Hospitalizations for Outpatients’ Adverse Drug Events: 12-Year Active Pharmacovigilance Surveillance (The MEREAFaPS Study). *Front Pharmacol*. 2020;11. doi:10.3389/fphar.2020.00412
 15. Convertino I, Tuccori M, **Ferraro S**, Valdiserra G, Cappello E, Focosi D, Blandizzi C. Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients. *Crit Care*. 2020;24(1):331. doi:10.1186/s13054-020-03020-3
 16. Convertino I, Salvadori S, Pecori A, Galiulo MT, **Ferraro S**, Parrilli M, Corona T, Turchetti G, Blandizzi C, Tuccori M. Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis. *Drug Saf*. 2019;42(3). doi:10.1007/s40264-018-0737-0
 17. **Ferraro S**, Convertino I, Leonardi L, Blandizzi C, Tuccori M. Unresolved gustatory, olfactory and auditory adverse drug reactions to antibiotic drugs: a survey of spontaneous reporting to Eudravigilance. *Expert Opin Drug Saf*. 2019;18(12):1245-1253. doi:10.1080/14740338.2019.1676724
 18. **Ferraro S**, Leonardi L, Convertino I, Blandizzi C, Tuccori M. Is there a risk of lymphoma associated with antitumor necrosis factor drugs in patients with inflammatory bowel disease? a systematic review of observational studies. *Front Pharmacol*. 2019;10. doi:10.3389/fphar.2019.00247
 19. Convertino I, **Ferraro S**, Blandizzi C, Tuccori M. The usefulness of listening social media for pharmacovigilance purposes: a systematic review. *Expert Opin Drug Saf*. 2018;17(11). doi:10.1080/14740338.2018.1531847

Abstracts published in journal

- 1) Roberto G, Paoletti O, **Ferraro S**, Hyeraci G, Gini R, Focosi D, Tuccori M. Acquired Hemophilia A and COVID19 Vaccines: A Possible Safety Signal or a Notoriety/Detection Bias? *Drug Saf*; 1314; 2022
- 2) Bonaso M, Marchione P, Felicetti P, Pentronzelli F, Cappello E, Samez S, Zappetti C, Rossi P, Merlano C, Valdiserra G, **Ferraro S**, Convertino I, Marra AR, Parrilli M, Tuccori M. COVID-19 Vaccines and Thromboembolic Events with Thrombocytopenia: Data from Italian Pharmacovigilance Public Database. *Drug Saf*; 1202; 2022
- 3) Bonaso M, Moretti U, Valdiserra G, Cappello E, Convertino I, **Ferraro S**, Tuccori M. Signal of Hypertension Associated with COVID-19 Vaccination: VigiBase: Data and Evidence from Real World. *Drug Saf*; 1121; 2022
- 4) **Ferraro S**, Paoletti O; Giometto S; Tillati S; Convertino I; Valdiserra G; Cappello E; Bonaso M; Bartolini C; Lorenzoni V; Turchetti G; Gini R; Fornai M; Lucenteforte E; Tuccori M. Evaluation of drug-utilization and healthcare facilities use in patients with ulcerative colitis and treated with biologic therapy using data of an Italian healthcare administrative database: Results from MICHELANGELO study. *Pharmacoepidemiol Drug Saf*; 363;2022
- 5) Convertino I, Cazzato M, Tillati S, Giometto S, Gini R, Valdiserra G, Cappello E, **Ferraro S**, Bonaso M, Bartolini C, Paoletti O, Lorenzoni V, Filippi M, Turchetti G, Cristofano M, Blandizzi C, Mosca M, Lucenteforte E, Tuccori M. Exploring the relationship between utilization patterns of biologic disease-modifying-rheumatic drugs and disease activity in rheumatoid arthritis patients. *Pharmacoepidemiol Drug Saf*; 488; 2022
- 6) **Ferraro S**, Bartolini C, Convertino I, Bertani Lorenzo, Giometto Sabrina, Cappello E, Valdiserra G, Tillati S, Blandizzi C, Lucenteforte E, Costa F, Gini R, Tuccori M. Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn's disease: Data from administrative databases in Tuscany, Italy. *Pharmacoepidemiol Drug Saf*; 2021
- 7) Lorenzoni V, Tuccori M, Gini R, Fini E, Giometto S, Bartolini C, Paoletti O, Convertino I, **Ferraro S**, Cappello E, Valdiserra G, Blandizzi C, Lucenteforte E, Turchetti G. Direct health costs among patients with rheumatoid arthritis before and after the initiation of treatment with JAKi in Tuscany: The LEONARDO study. *Pharmacoepidemiol Drug Saf*; 2021
- 8) Claudia Bartolini; **Sara Ferraro**; Irma Convertino; Lorenzo Bertani; Sabrina Giometto; Francesco Costa; Corrado Blandizzi; Ersilia Lucenteforte; Rosa Gini; Marco Tuccori. Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy). *Pharmacoepidemiol Drug Saf*; 2021
- 9) Giometto S, Convertino I, Tuccori M, Gini R, Cazzato M, Valdiserra G, Cappello E, **Ferraro S**, Tillati S, Fornili M, Bartolini C, Paoletti O, Turchetti G, Trieste L, Lorenzoni V, Blandizzi C, Mosca M, Lucenteforte E. Longitudinal adherence trajectories to biologic disease modifying anti-rheumatic drgs in Tuscany, Italy. *Pharmacoepidemiol Drug Saf*; 2021
- 10) Bartolini C, **Ferraro S**, Convertino I, Bertani Lorenzo, Giometto Sabrina, Costa F, Lucenteforte E, Cappello E, Valdiserra G, Blandizzi C, Gini R, Tuccori M. Trajectories of oral budesonide use in Crohn's disease cohort of Tuscan patients (Italy). *Pharmacoepidemiol Drug Saf*; 2021
- 11) Tuccori M, Lorenzoni V, Gini R, Turchetti G, Fini E, Giometto S, Bartolini C, Paoletti O, Convertino I, **Ferraro S**, Cappello E, Valdiserra G, Blandizzi C, Lucenteforte E. Utilization patterns and healthcare accesses of JAKi used in rheumatoid arthritis patients in Tuscany: The LEONARDO study. *Pharmacoepidemiol Drug Saf*; 2021
- 12) Convertino I, Cazzato M, Giometto S, Gini R, Valdiserra G, Cappello E, **Ferraro S**, Tillati S, Fornili M, Bartolini C, Paoletti O, Lorenzoni V, Trieste L, Filippi M, Turchetti G, Cristofano M, Blandizzi C, Mosca M, Tuccori M. Validation test for algorithms to identify rheumatoid arthritis patients in the Tuscan healthcare administrative databases. *Pharmacoepidemiol Drug Saf*.
- 13) Valdiserra G, **Ferraro S**, Fornili M, Convertino I, Cappello E, Lucenteforte E, Tuccori M. Unresolved Gustatory, Olfactory and Auditory Adverse Drug Reactions to Antibiotic Drugs: A Signal Detection Analysis on Publicly Accessible Eudravigilance Data. *Drug Safety*, 2021
- 14) Valdiserra G, Tillati S, Lorenzoni V, Gini R, Turchetti G, Giometto S, Bartolini C, Paoletti O, Convertino I, **Ferraro S**, Cappello E, Fornai M, Lucenteforte E, Tuccori M. Accesses to Emergency Department and Hospitalizations in New Users of Biologic Therapies for Ulcerative Colitis in Tuscany: The MICHELANGELO Study. *Drug Safety*, 2021
- 15) **Ferraro S**, Bartolini C, Bertani L, Convertino I, Lucenteforte E, Costa F, Valdiserra G, Cappello E, Blandizzi C, Gini R, Tuccori M. Time to biologic treatment and to total colectomy associated with diagnostic delay in ulcerative colitis: Analysis of an Italian regional administrative healthcare database. *Pharmacoepidemiol Drug Saf*. 2020;29:612.
- 16) Convertino I, Giometto S, Gini R, Cazzato M, Valdiserra G, Cappello E, **Ferraro S**, Fornili M, Turchetti G, Lorenzoni V, Trieste L, Mosca M, Blandizzi C, Tuccori M, Lucenteforte E. Trajectories of use of biologic disease modifying

antirheumatic drugs in rheumatoid arthritis: A cohort study of Tuscan patients, Italy. *Pharmacoepidemiol Drug Saf.* 2020;29:246. doi:DOI: 10.1002/pds.5114

- 17) Blandizzi C, Tuccori M, **Ferraro S**, Leonardi L, Convertino I. Anti-tumor Necrosis Factor Drugs and Risk of Lymphoma in Patients with Inflammatory Bowel Disease. *DRUG Saf.* 2019;42:1245. doi:10.1007/s40264-019-00855-w
- 18) Convertino I, Leonardi L, Tuccori M, **Ferraro S**, Salvadori S, Franchini M, De Carlo I, Kirchmayer U, Corona T, Riengler S, Menditto E, Parrilli M, Rossi M, Orlando V, Pieroni S, Vannacci A. Anticoagulant Therapy and Risk of Bleeding in Patients with Atrial Fibrillation of Four Italian Regions: The TYRION Study. *DRUG Saf.* 2019;42:1211-1212. doi:10.1007/s40264-019-00855-w
- 19) **Ferraro S**, Leonardi L, Blandizzi C, Convertino I, Tuccori M. Antibiotic Drugs and Unresolved Sensory Side Effects: Analysis of Eudravigilance Database of Suspected Adverse Drug Reaction Reports. *DRUG Saf.* 2019;42:1207-1208. doi:10.1007/s40264-019-00855-w
- 20) Convertino I, Lucenteforte E, Lorenzoni V, Turchetti G, Trieste L, Roberto G, Cazzato M, Mosca M, **Ferraro S**, Leonardi L, Luciano N, Gini R, Blandizzi C, Tuccori M. Recommendations by the Tuscan Health Authority to Use Infliximab-Biosimilar in the Clinical Practice: Safety Impact. *DRUG Saf.* 2019;42:1217. doi:10.1007/s40264-01900855-w
- 21) Convertino I, Leonardi L, Tuccori M, **Ferraro S**, Blandizzi C. Listening Social Media for Pharmacovigilance Objectives: Which Usefulness? *DRUG Saf.* 2019;42:1245-1246. doi:10.1007/s40264-019-00855-w
- 22) Leonardi L, Fornili M, Convertino I, Lucenteforte E, Del Lungo M, **Ferraro S**, Blandizzi C, Giovannetti L, Baglietto L, Parrilli M, Borsi V, Di Giorgio D. The Anti-TNF Drugs and the Risk of Lymphoma, Skin Cancer and Melanoma: A Signal Detection Analysis. *DRUG Saf.* 2019;42:1270-1271. doi:10.1007/s40264-019-00855-w
- 23) Lorenzoni V, Trieste L, Mosca M, Convertino I, Tuccori M, Lucenteforte E, **Ferraro S**, Leonardi L, Roberto G, Luciano N, Blandizzi C, Gini R, Turchetti G. The Economic Impact of the Introduction of Infliximab-Biosimilar: Preliminary Results from a Study on Rheumatologic Patients in Tuscany, Italy. *Pharmacoepidemiol Drug Saf.* 2019;28:9. doi:10.1002/pds.4864
- 24) Convertino I, Tuccori M, Lucenteforte E, Mosca M, Turchetti G, Lorenzoni V, Trieste L, **Ferraro S**, Leonardi L, Roberto G, Luciano N, Blandizzi C, Gini R. Switching from infliximab-originator to infliximab-biosimilar in rheumatologic patients: The clinical impact in Tuscan Region, Italy. *Pharmacoepidemiol Drug Saf.* 2019;28:477-478. doi:10.1002/pds.4864
- 25) Lorenzoni V, Convertino I, Lucenteforte E, **Ferraro S**, Leonardi L, Roberto G, Luciano N, Cazzato M, Blandizzi C, Gini R, Tuccori M, Mosca M, Turchetti G. The economic impact of the introduction of infliximab-biosimilar: an empirical analysis using the tuscany healthcare administrative databases. *VALUE Heal.* 2019;22:S434--S434. doi:10.1016/j.jval.2019.09.194
- 26) **Ferraro S**, Convertino I, Salvadori S, Pieroni S, Pecori A, Franchini M, De Carlo I, Kirchmayer U, Corona T, Parrilli M, Rossi M, Vannacci A, Blandizzi C, Tuccori M. Anticoagulant Therapy in Patients with Atrial Fibrillation and Risk of Bleeding: Interim Analysis: Tyrion Study. *DRUG Saf.* 2018;41:1218. doi:10.1007/s40264-018-0719-2
- 27) Convertino I, Salvadori S, Pecori A, Galiulo M, **Ferraro S**, Parrilli M, Corona T, Turchetti G, Blandizzi C, Tuccori M. A Model-Based Analysis on Direct Costs of Adverse Drug Events and Related Cost-Savings Achievable by their Prevention in Tuscany, Italy. *DRUG Saf.* 2018;41:1210-1211. doi:10.1007/s40264-018-0719-2